Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ZYUS Life Sciences Corp

ZYUS.V ✓ COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: BUY

Last Close

$0.36

▲ +0.00%

Market Cap $28.61M · Vol 3.02K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$28.61M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+53.09%

YoY

RSI (14)

50.00

Momentum

Beta

0.24

vs Market

52W High

$0.53

32.59% below

52W Low

$0.28

25.18% above

Volume

3.02K

Avg 0

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

48.55%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ZYUS Life Sciences Corp (ZYUS.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZYUS.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-23.85%

YTD

-29.29%

-31.25%

-55.45%

-60.40%

Financials & Valuation

TTM · Annual

Total Revenue	$295.10K
Net Income	$-15,834,305.00
Revenue Growth (YoY)	+7.02%
Gross Margin	-660.25%
Operating Margin	-3,503.46%
Net Profit Margin	-5,365.68%
ROE	N/A
ROA · ROIC	-220.07% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	132.76
P/B	N/A
P/FCF	N/A
EPS Growth	+53.09%
Outstanding Shares	80.52M

Technical Indicators

50-Day SMA	$0.36
200-Day SMA	$0.42
RSI (14)	50.00
Beta	0.24
52-Week High	$0.53
52-Week Low	$0.28

Volume Today	3.02K
Avg Daily Volume (30D)	0
Relative Volume	N/Ax
Volatility (10D)	0.00
Volatility (30D)	0.00
Free Float	48.55%

Analyst Consensus

BUY

Current Price $0.36

Mean Target N/A

52W Low$0.28 52W High$0.53

Current

Target

$0.28 $0.53

Current Analyst target

· 1 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG001S5ZYJ2

ISINCA9899601095

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateFeb 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

ZYUS Life Sciences Corporation is a Canada-based life sciences company focused on developing and commercializing cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.